19th May, 2021
COVID-19 vaccines dose-sharing and surged production can protect the world’s population, says IPHA
Industry urges partnership in the effort to equitably vaccinate all priority populations globally
The Irish Pharmaceutical Healthcare Association (IPHA), which represents the originator biopharmaceutical industry, has urged the Government to support global collaborative efforts to step up responsible COVID-19 vaccine dose-sharing and maximise production without compromising quality or safety.
IPHA, in partnership with EFPIA, the industry’s European representative body, and other organisations said vaccines-makers, governments and non-governmental organisations must work together to ensure that COVID-19 vaccine doses equitably reach all priority populations globally.
The originator biopharmaceutical industry has brought forward COVID-19 vaccine breakthroughs in record time. After more than 200 clinical trials and nearly 300 partnerships and collaborations among vaccines-makers globally, production has risen in just a few months from zero to 2.2 billion COVID-19 vaccine doses by the end of May.
By the end of this year, analysts are predicting 11 billion COVID-19 vaccine doses will have been produced – enough doses to vaccinate the world’s adult population.
But COVID-19 vaccines are not equally reaching all priority populations worldwide. The industry, in Europe and globally, outlined steps it believes can change that.
Oliver O’Connor, Chief Executive of IPHA, said: “Our industry wants to see the COVID-19 vaccines it discovered at record speed produced in enough quantities that can equitably meet global demand in the shortest possible timeframe. The focus is on responsible COVID-19 vaccine dose-sharing and maximising production without compromising quality or safety. We are continuing to innovate for the discovery of new vaccines and treatments for variants of concern. We would ask our government to support the five steps we have outlined which we believe form the pathway to steeling the world against further waves of infection.”
IPHA has urged the protection of intellectual property rights which have been the basis for the discovery of new COVID-19 vaccines and treatments at unprecedented pace. “That research-based response, with Europe at its heart, has given us the tools to fight the virus,” said Mr O’Connor.